Charles Kasozi
Biographic Data
| ID | 7448006 |
|---|---|
| NAME | Charles Kasozi |
| GIVEN NAMES | Charles |
| FAMILY NAME | Kasozi |
| SIGNATURE | KASOZI C |
| AFFILIATIONS | Masaka Hospital |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Lingering sex and age disparities in dolutegravir uptake among adults with HIV
INTRODUCTION: Since July 2019, the WHO has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy (ART) for adults and adolescents living with HIV (DTG-for-All), a reversal of a 2018 safety alert on use of DTG-based regimens by women of reproductive age (WRA). We examined sex and age disparities in DTG uptake before and after DTG-for-All in the International epidemiology Databases to Evaluate AIDS. METHODS: W…
Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium
Availability of screening and treatment for AUD/SUD in HIV care settings is limited, leaving a substantial gap for integration into ongoing HIV care. A critical understanding is needed of the multilevel implementation factors or feasible implementation strategies for integrating screening and treatment of AUD/SUD into HIV care settings, particularly for resource-constrained regions
No prominent works on this page.
Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium
Availability of screening and treatment for AUD/SUD in HIV care settings is limited, leaving a substantial gap for integration into ongoing HIV care. A critical understanding is needed of the multilevel implementation factors or feasible implementation strategies for integrating screening and treatment of AUD/SUD into HIV care settings, particularly for resource-constrained regions
Lingering sex and age disparities in dolutegravir uptake among adults with HIV
INTRODUCTION: Since July 2019, the WHO has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy (ART) for adults and adolescents living with HIV (DTG-for-All), a reversal of a 2018 safety alert on use of DTG-based regimens by women of reproductive age (WRA). We examined sex and age disparities in DTG uptake before and after DTG-for-All in the International epidemiology Databases to Evaluate AIDS. METHODS: W…
HIV/AIDS Research and Interventions (2 works) · Alcohol (1 works) · Alcohol use disorder (1 works) · Cohort study (1 works) · Cumulative incidence (1 works) · Dolutegravir (1 works) · Environmental health (1 works) · Epidemiology (1 works) · Family medicine (1 works) · HIV-related health complications and treatments (1 works)